Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1987 1
1989 2
1990 2
1991 3
1992 1
1994 1
1996 2
1999 1
2000 1
2001 2
2002 1
2004 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate.
Rau R, Simianer S, van Riel PL, van de Putte LB, Krüger K, Schattenkirchner M, Allaart CF, Breedveld FC, Kempeni J, Beck K, Kupper H. Rau R, et al. Among authors: kempeni j. Scand J Rheumatol. 2004;33(3):145-53. doi: 10.1080/03009740410005467. Scand J Rheumatol. 2004. PMID: 15228184 Clinical Trial.
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J. Reinhart K, et al. Among authors: kempeni j. Crit Care Med. 1996 May;24(5):733-42. doi: 10.1097/00003246-199605000-00003. Crit Care Med. 1996. PMID: 8706447 Clinical Trial.
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.
Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, Tellado JM, Salgado-Remigio A, Zimlichman R, Withington S, Tschaikowsky K, Brase R, Damas P, Kupper H, Kempeni J, Eiselstein J, Kaul M. Reinhart K, et al. Among authors: kempeni j. Crit Care Med. 2001 Apr;29(4):765-9. doi: 10.1097/00003246-200104000-00015. Crit Care Med. 2001. PMID: 11373466 Clinical Trial.
19 results